Why Has Deutsche Bank Given NovoCure (NASDAQ:NVCR) a $28.0 Price Target
Research analysts at Deutsche Bank have initiated coverage on shares of NovoCure (NASDAQ:NVCR) in a very recent research note issued on 2 December. The firm set Hold rating on the stock. Deutsche Bank’s target price of $28.0 suggests potential of 16.33% from the stock’s closing share price.
From a total of 4 analysts covering NovoCure (NASDAQ:NVCR) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $43 while the lowest target price is $29. The mean of all analyst targets is $32.75 with a 35.08% above today’s ($24.06) stock price. NovoCure was the topic of 4 analyst reports since October 27, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank initiated shares on December 2 with “Hold” rating. JP Morgan initiated NVCR stock in a recent report from October 27 with “Overweight” rating.
The stock decreased 0.04% or $0.01 on December 2, striking $24.06. Approximately 170,147 shares of stock traded hands. Novocure Ltd (NASDAQ:NVCR) has risen 6.00% since November 2, 2015 and is uptrending. It has outperformed by 6.20% the S&P500.
NovoCure Limited is a commercial-stage oncology company. The company has a market cap of $1.97 billion. The Firm is engaged in developing a therapy called Tumor Treating Fields (TTFields), for the treatment of solid tumor cancers. It currently has negative earnings. The Company’s TTFields is an anti-mitotic treatment.
According to Zacks Investment Research, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.” Get a free copy of the Zacks research report on Novocure Ltd (NVCR).